Joanna Przybyl
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Joanna Przybyl has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
- Matt van de Rijn
Department of Pathology, Stanford University, Stanford, California
93 shared publications - Benjamin Aaron Alman
Department of Orthopaedic Surgery, Duke University, NC, USA
71 shared publications - Mushriq Al-Jazrawe
Harvard Medical School, Boston, MA, USA
71 shared publications - Qingxia Wei
Hospital for Sick Children, Program in Developmental & Stem Cell Biology, Toronto, Ontario, Canada
71 shared publications - Raymond Poon
Hospital for Sick Children, Program in Developmental & Stem Cell Biology, Toronto, Ontario, Canada
71 shared publications - Steven Xu
Hospital for Sick Children, Program in Developmental & Stem Cell Biology, Toronto, Ontario, Canada
71 shared publications
Latest Publications
- Open Access
Machine Learning Analysis to Define Cell Lineage in Leiomyosarcoma
Introduction: Cellular differentiation and lineage commitment are known to be associated with differences in DNA methylation. Leiomyosarcoma (LMS) is a tumor thought to originate from smooth muscle cells in the walls of vessels in the soft tissue (STLMS) or from the uterine myometrium (ULMS). Here, we identify the methylation signatures of normal smooth muscle cells from blood vessels and the uterine wall and compare these with those found in STLMS and ULMS. We hypothesized that these methylation signatures could be used to assign a smooth muscle subtype of origin to individual leiomyosarcomas, and that tumors of different origin would show biological differences with potential therapeutic relevance. Methods: To define methylation profiles for smooth muscle from vessel walls versus those found in myometrium, EPIC methylation profiling was performed on DNA from 49 formalin-fixed paraffin-embedded (FFPE) normal smooth muscle samples. A supervised machine learning algorithm (Random Forest) was used to distinguish the methylation patterns of normal smooth muscle cells in vessel walls from those in the myometrium. The resulting classifier was applied to methylation data on 67 cases of LMS with corresponding bulk RNAseq data to identify which tumors showed a methylation signature most consistent with either blood vessel wall (LMS vessel ) or myometrial smooth muscle (LMS wall ). A custom signature matrix derived from scRNAseq data from 6 samples of LMS was used in CIBERSORTx analysis to compare the cellular composition of LMS cases with a vessel or uterine wall methylation signature. Results: A high degree of correlation was found between the known site of origin for LMS (STLMS vs ULMS) and the methylation signature derived from different types of normal smooth muscle. LMS wall tumors compared to LMS vessel tumors had significantly higher activation of the PD-1 checkpoint pathway in RNAseq analysis. Digital flow cytometry by CIBERSORTx analysis showed an increased expression of transcriptomic signatures of several immune cell subtypes in LMS vessel tumors. Conclusion: Using a supervised machine learning approach we classified LMS samples as either showing a high similarity in methylation patterns to normal smooth muscle cells of either the vessel wall or the myometrium. We found a correlation between LMS showing either a “vessel” or “muscle wall” methylation signature and their site of origin, but notably we also identified some exceptions. When classified based on their methylation signature LMS wall and LMS vessel differed in their PD-1 pathway activation and in their predicted immune cell populations, suggesting potential implications for immunotherapeutic approaches.
Open AccessMachine Learning Analysis to Define Cell Lineage in Leiomyosarcoma
Introduction: Cellular differentiation and lineage commitment are known to be associated with differences in DNA methylation. Leiomyosarcoma (LMS) is a tumor thought to originate from smooth muscle cells in the walls of vessels in the soft tissue (STLMS) or from the uterine myometrium (ULMS). Here, we identify the methylation signatures of normal smooth muscle cells from blood vessels and the uterine wall and compare these with those found in STLMS and ULMS. We hypothesized that these methylation signatures could be used to assign a smooth muscle subtype of origin to individual leiomyosarcomas, and that tumors of different origin would show biological differences with potential therapeutic relevance. Methods: To define methylation profiles for smooth muscle from vessel walls versus those found in myometrium, EPIC methylation profiling was performed on DNA from 49 formalin-fixed paraffin-embedded (FFPE) normal smooth muscle samples. A supervised machine learning algorithm (Random Forest) was used to distinguish the methylation patterns of normal smooth muscle cells in vessel walls from those in the myometrium. The resulting classifier was applied to methylation data on 67 cases of LMS with corresponding bulk RNAseq data to identify which tumors showed a methylation signature most consistent with either blood vessel wall (LMS vessel ) or myometrial smooth muscle (LMS wall ). A custom signature matrix derived from scRNAseq data from 6 samples of LMS was used in CIBERSORTx analysis to compare the cellular composition of LMS cases with a vessel or uterine wall methylation signature. Results: A high degree of correlation was found between the known site of origin for LMS (STLMS vs ULMS) and the methylation signature derived from different types of normal smooth muscle. LMS wall tumors compared to LMS vessel tumors had significantly higher activation of the PD-1 checkpoint pathway in RNAseq analysis. Digital flow cytometry by CIBERSORTx analysis showed an increased expression of transcriptomic signatures of several immune cell subtypes in LMS vessel tumors. Conclusion: Using a supervised machine learning approach we classified LMS samples as either showing a high similarity in methylation patterns to normal smooth muscle cells of either the vessel wall or the myometrium. We found a correlation between LMS showing either a “vessel” or “muscle wall” methylation signature and their site of origin, but notably we also identified some exceptions. When classified based on their methylation signature LMS wall and LMS vessel differed in their PD-1 pathway activation and in their predicted immune cell populations, suggesting potential implications for immunotherapeutic approaches.
- Open Access
- 11 May 2026
- Published by Wiley in Journal of Cellular Physiology
- Vol. 241 (5) , e70182
Decoding the Hexosamine Biosynthesis Pathway: Implications for Novel Therapeutic Strategies in Sarcoma
Cancer cells rewire their metabolism to sustain a high proliferation rate. Sensing external cues is essential to match the metabolic fluxes of the cells to the external stimuli. As part of the glucose metabolism, the hexosamine biosynthesis pathway (HBP) is considered a nutrient‐sensing pathway. The HBP produces UDP‐GlcNAc, a key precursor for N‐linked glycosylation, O‐linked glycosylation, and O‐GlcNAcylation. These post‐translational modifications can influence protein folding, interactions, and subcellular localization. Altered glycosylation of oncogenic proteins has been linked to the acquisition of malignant properties. In this review, we outline the current knowledge of molecular alterations and the prognostic role of the expression of HBP enzymes in sarcoma. We catalog the known sites of N‐/O‐linked glycosylation and O‐GlcNAc modifications in molecular drivers of mesenchymal tumors, and discuss the potential effect of these modifications on protein function. We also summarize the studies that examined the effect of the HBP inhibitors in preclinical models of cancer, and explore the potential of the HBP inhibition as a novel therapeutic approach for sarcoma. Finally, we present recent progress in drug development for targeting the HBP, and delineate the key technological innovations needed to accelerate the preclinical and clinical research on pharmacological inhibition of the HBP.
- 11 May 2026
- Published by Wiley in Journal of Cellular Physiology
- Vol. 241 (5) , e70182
Open AccessDecoding the Hexosamine Biosynthesis Pathway: Implications for Novel Therapeutic Strategies in Sarcoma
Cancer cells rewire their metabolism to sustain a high proliferation rate. Sensing external cues is essential to match the metabolic fluxes of the cells to the external stimuli. As part of the glucose metabolism, the hexosamine biosynthesis pathway (HBP) is considered a nutrient‐sensing pathway. The HBP produces UDP‐GlcNAc, a key precursor for N‐linked glycosylation, O‐linked glycosylation, and O‐GlcNAcylation. These post‐translational modifications can influence protein folding, interactions, and subcellular localization. Altered glycosylation of oncogenic proteins has been linked to the acquisition of malignant properties. In this review, we outline the current knowledge of molecular alterations and the prognostic role of the expression of HBP enzymes in sarcoma. We catalog the known sites of N‐/O‐linked glycosylation and O‐GlcNAc modifications in molecular drivers of mesenchymal tumors, and discuss the potential effect of these modifications on protein function. We also summarize the studies that examined the effect of the HBP inhibitors in preclinical models of cancer, and explore the potential of the HBP inhibition as a novel therapeutic approach for sarcoma. Finally, we present recent progress in drug development for targeting the HBP, and delineate the key technological innovations needed to accelerate the preclinical and clinical research on pharmacological inhibition of the HBP.
- Open Access
- 6 January 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 7 from Genomic, Epigenomic, and Transcriptomic Inter- and Intratumor Heterogeneity in Desmoid Tumors
Supplementary Table 7. Normalized gene expression values of the 10% most variable genes in tumor specimens from Patient 3.
- 6 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 7 from Genomic, Epigenomic, and Transcriptomic Inter- and Intratumor Heterogeneity in Desmoid Tumors
Supplementary Table 7. Normalized gene expression values of the 10% most variable genes in tumor specimens from Patient 3.
- Open Access
- 6 January 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 8 from Genomic, Epigenomic, and Transcriptomic Inter- and Intratumor Heterogeneity in Desmoid Tumors
Supplementary Table 8. Antibodies used for immunohistochemistry.
- 6 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 8 from Genomic, Epigenomic, and Transcriptomic Inter- and Intratumor Heterogeneity in Desmoid Tumors
Supplementary Table 8. Antibodies used for immunohistochemistry.
- Open Access
- 6 January 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Genomic, Epigenomic, and Transcriptomic Inter- and Intratumor Heterogeneity in Desmoid Tumors
Supplementary Figure 2. Validation of the S45F mutation in the CTNNB1 gene in recurrent tumor specimen STT8702 of Patient 3.
- 6 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Genomic, Epigenomic, and Transcriptomic Inter- and Intratumor Heterogeneity in Desmoid Tumors
Supplementary Figure 2. Validation of the S45F mutation in the CTNNB1 gene in recurrent tumor specimen STT8702 of Patient 3.
- Open Access
- 6 January 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Genomic, Epigenomic, and Transcriptomic Inter- and Intratumor Heterogeneity in Desmoid Tumors
Supplementary Table 1. Sequencing statistics and quality control metrics.
- 6 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Genomic, Epigenomic, and Transcriptomic Inter- and Intratumor Heterogeneity in Desmoid Tumors
Supplementary Table 1. Sequencing statistics and quality control metrics.
- Open Access
- 6 January 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 13 from Genomic, Epigenomic, and Transcriptomic Inter- and Intratumor Heterogeneity in Desmoid Tumors
Supplementary Table 13. Variant allele fraction of clonal and subclonal point mutations supported by RNA-seq reads in Patient 1 (in genomic positions supported by >10 reads coverage and present in both forward and reverse reads).
- 6 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 13 from Genomic, Epigenomic, and Transcriptomic Inter- and Intratumor Heterogeneity in Desmoid Tumors
Supplementary Table 13. Variant allele fraction of clonal and subclonal point mutations supported by RNA-seq reads in Patient 1 (in genomic positions supported by >10 reads coverage and present in both forward and reverse reads).
- Open Access
- 6 January 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 15 from Genomic, Epigenomic, and Transcriptomic Inter- and Intratumor Heterogeneity in Desmoid Tumors
Supplementary Table 15. Expression of MLH1, MSH2, MSH6 and PMS2 proteins evaluated by immunohistochemistry in duplicate cores of primary and recurrent tumor specimens obtained from 2 patients.
- 6 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 15 from Genomic, Epigenomic, and Transcriptomic Inter- and Intratumor Heterogeneity in Desmoid Tumors
Supplementary Table 15. Expression of MLH1, MSH2, MSH6 and PMS2 proteins evaluated by immunohistochemistry in duplicate cores of primary and recurrent tumor specimens obtained from 2 patients.
- Open Access
- 6 January 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from Genomic, Epigenomic, and Transcriptomic Inter- and Intratumor Heterogeneity in Desmoid Tumors
Supplementary Table 4. RNA-seq paired reads mapped to protein coding genes in 31 specimens from 20 primary desmoid tumors.
- 6 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from Genomic, Epigenomic, and Transcriptomic Inter- and Intratumor Heterogeneity in Desmoid Tumors
Supplementary Table 4. RNA-seq paired reads mapped to protein coding genes in 31 specimens from 20 primary desmoid tumors.
- Open Access
- 6 January 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Genomic, Epigenomic, and Transcriptomic Inter- and Intratumor Heterogeneity in Desmoid Tumors
Supplementary Table 2. DNA copy number alterations detected in primary and recurrent tumor specimens of 3 patients.
- 6 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Genomic, Epigenomic, and Transcriptomic Inter- and Intratumor Heterogeneity in Desmoid Tumors
Supplementary Table 2. DNA copy number alterations detected in primary and recurrent tumor specimens of 3 patients.